Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) shares fell 4.1% during mid-day trading on Tuesday . The stock traded as low as $12.56 and last traded at $12.56. 42,943 shares traded hands during trading, a decline of 94% from the average session volume of 762,696 shares. The stock had previously closed at $13.10.
Analyst Ratings Changes
STOK has been the subject of several research analyst reports. Wedbush restated an "outperform" rating and issued a $17.00 price objective on shares of Stoke Therapeutics in a report on Thursday, July 11th. Leerink Partners started coverage on Stoke Therapeutics in a research report on Monday, October 14th. They issued an "outperform" rating and a $18.00 price objective on the stock. Leerink Partnrs raised shares of Stoke Therapeutics to a "strong-buy" rating in a report on Friday, October 11th. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, September 11th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $20.83.
Read Our Latest Report on Stoke Therapeutics
Stoke Therapeutics Stock Performance
The business's fifty day simple moving average is $13.25 and its 200-day simple moving average is $13.71. The company has a market capitalization of $687.08 million, a P/E ratio of -5.99 and a beta of 0.95.
Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.11. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. The firm had revenue of $4.83 million during the quarter, compared to analysts' expectations of $3.33 million. As a group, analysts forecast that Stoke Therapeutics, Inc. will post -2.1 EPS for the current year.
Insider Buying and Selling
In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of the business's stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the completion of the transaction, the insider now owns 8,906,181 shares in the company, valued at $125,131,843.05. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 11.30% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. bought a new position in Stoke Therapeutics in the 1st quarter worth about $1,224,000. BNP Paribas Financial Markets increased its holdings in Stoke Therapeutics by 86.2% during the 1st quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company's stock worth $193,000 after purchasing an additional 6,636 shares during the period. State Board of Administration of Florida Retirement System purchased a new position in Stoke Therapeutics during the 1st quarter worth $141,000. Vanguard Group Inc. raised its position in Stoke Therapeutics by 4.1% during the 1st quarter. Vanguard Group Inc. now owns 1,715,554 shares of the company's stock valued at $23,160,000 after purchasing an additional 67,052 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in shares of Stoke Therapeutics by 10.2% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 263,700 shares of the company's stock worth $3,560,000 after buying an additional 24,400 shares during the period.
About Stoke Therapeutics
(
Get Free Report)
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
Featured Stories
Before you consider Stoke Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.
While Stoke Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
